Literature DB >> 21435910

Reversible dementia and gait disturbance after prolonged use of valproic acid.

Matthew D Evans1, Ron Shinar, Roy Yaari.   

Abstract

Valproic acid (VPA) has been reported to cause cognitive decline and parkinsonism that are reversed with cessation of medication. Common imaging findings among these reports demonstrate reversible cortical pseudoatrophy and enlargement of the lateral ventricles. This case exemplifies these adverse effects of VPA which can cause reversible neurological symptoms even in long-term treated patients and can present as dementia syndromes such as normal pressure hydrocephalus.
Copyright © 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21435910     DOI: 10.1016/j.seizure.2011.02.009

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  5 in total

Review 1.  Management of Gait Changes and Fall Risk in MCI and Dementia.

Authors:  Gilles Allali; Joe Verghese
Journal:  Curr Treat Options Neurol       Date:  2017-09       Impact factor: 3.598

2.  Reversible dementia and gait disturbance as a result of polypharmacy.

Authors:  Monica Gupta; Ram Singh; Kamal Singh; S S Lehl
Journal:  BMJ Case Rep       Date:  2013-03-25

3.  Chronic divalproex sodium use and brain atrophy in Alzheimer disease.

Authors:  A S Fleisher; D Truran; J T Mai; J B S Langbaum; P S Aisen; J L Cummings; C R Jack; M W Weiner; R G Thomas; L S Schneider; P N Tariot
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

Review 4.  Valproate-Associated Parkinsonism: A Critical Review of the Literature.

Authors:  Florian Brugger; Kailash P Bhatia; Frank M C Besag
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

5.  The Association between Polypharmacy and Dementia: A Nested Case-Control Study Based on a 12-Year Longitudinal Cohort Database in South Korea.

Authors:  Hae-Young Park; Ji-Won Park; Hong Ji Song; Hyun Soon Sohn; Jin-Won Kwon
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.